Arena Pharma (ARNA) Tops Q1 EPS by 4c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Arena Pharma (ARNA) BELVIQ Trends Remain Underwhelming, BMO Capital Notes
May 12, 2015 8:52 AM EDTBMO Capital analyst Jim Birchenough reiterated a Market Perform rating and $9 price target on Arena Pharma (NASDAQ: ARNA) following Q1 results, with BELVIQ trends remaining underwhelming.
Birchenough commented, "We are maintaining our Market Perform rating on the shares of ARNA following review of... More
Arena Pharma (ARNA) Unit, Roivant Sciences Enter Nelotanserin Development, Supply Agreement
May 11, 2015 4:04 PM EDTArena Pharma (NASDAQ: ARNA) announced that its subsidiary, Arena Pharmaceuticals GmbH, and Roivant Sciences Ltd., have entered into a Development, Marketing and Supply Agreement for nelotanserin, Arena's internally discovered inverse agonist of the 5-HT2A receptor. The agreement grants Roivant exclusive worldwide rights to develop and commercialize nelotanserin.
Nelotanserin has been studied to date in multiple clinical trials involving over 900 subjects. Roivant intends to initiate additional Phase 2 clinical trials for the treatment of behavioral and... More
